Nicole Chase, MD; S Shahzad Mustafa, MD; Sande Okelo, MD, and Robert Sporter, MD, examine the distinct manifestations of asthma stemming from allergic and non-allergic origins, as well as the factors contributing to its exacerbation.
At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.
Children with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.